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ABSTRACT
Background: Patients with chronic renal insufficiency, especially those un-
dergoing continuous ambulatory peritoneal dialysis (CAPD), normally have insulin 
resistance due to deficiencies in insulin secretion and degradation, as well as tissue
resistance to insulin at both receptor and postreceptor levels.
Objective: The aim of this study was to investigate the effectiveness and
tolerability of rosiglitazone on insulin resistance and body composition in patients 
without diabetes mellitus (DM) undergoing CAPD.
Methods: This pilot study included a pretest and posttest with a repeated-
measure design in a small number of patients. CAPD patients without DM received 
rosiglitazone 2-mg tablets BID for 12 weeks. Homeostasis Model Assessment Index
of Insulin Resistance (HOMA-IR) and bioelectrical impedance analysis (BIA) were 
used to assess insulin resistance and body composition, respectively. Tolerability was
assessed using laboratory analyses as well as physical examination findings to evaluate
peripheral edema. Peripheral edema was assessed by the study investigators.
Results: Thirteen Thai patients (mean [SD] age, 54.17 [11.42] years [range,
35–85 years]; body mass index [BMI], >20 to <30 kg/m2; fasting blood glucose 
[FBG] concentration, <5.39 mmol/L) were included in the study. One patient was 
withdrawn due to illness unrelated to the study. No significant difference was found 
in FBG concentration between baseline and posttreatment (after 12 weeks of treat-
ment) (5.45 [0.59] vs 5.24 [0.51] mmol/L), but fasting plasma insulin concentrations
(28.50 [23.70] vs 10.15 [4.22] μIU/mL; P = 0.005) and HOMA-IR score (6.70
[5.23] vs 2.40 [1.15]; P = 0.011) were significantly lower. There were no significant
changes in weight or BMI from baseline to posttreatment. Seven subjects (58.3%)
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experienced weight gain at week 4, while 2 patients (16.7%) still had weight gain
after 12 weeks of treatment. A significant increase was found between baseline and
posttreatment in total body water (38.03 [4.55] vs 42.44 [5.99] L; P = 0.018), extra-
cellular fluid (20.24 [3.75] vs 26.22 [8.69] L; P = 0.005), plasma fluid (4.29 [0.80] 
vs 5.20 [0.93] L; P = 0.005), and interstitial fluid (14.99 [2.78] vs 17.68 [3.07] L;
P = 0.040). Using BIA, no significant changes were observed in intracellular fluid, fat 
mass, or liver function. After 12 weeks of rosiglitazone administration, 2 patients 
(16.7%) had mild edema. 
Conclusions: Rosiglitazone 2 mg BID for 12 weeks was associated with 
significantly improved insulin resistance in this small group of nondiabetic Thai 
patients undergoing CAPD. There was a significant increase in total body water and
extracellular fluid after administration of rosiglitazone for 12 weeks. There were no
significant changes in FBG, weight, or BMI. (Curr Ther Res Clin Exp. 2009;70:377–
389) © 2009 Excerpta Medica Inc.
Key words: rosiglitazone, insulin resistance, body composition, nondiabetic,
CAPD.
INTRODUCTION
Metabolic syndrome represents a cluster of disturbances that are risk factors for
cardiovascular disease, including type 2 diabetes mellitus (DM), abdominal obesity,
hypertension, and dyslipidemia.1 Studies have found an association between insulin 
resistance or compensatory hyperinsulinemia and kidney disease2 or atherosclerotic
cardiovascular disease.3 Patients with chronic renal insufficiency, especially those un-
dergoing continuous ambulatory peritoneal dialysis (CAPD), normally have insulin
resistance due to deficiencies in insulin secretion and degradation, as well as tissue 
resistance to insulin at both receptor and postreceptor levels.4 Moreover, the dialysis 
solutions used in CAPD cause an additional glucose load of 100 to 300 g/d, resulting 
in tissue resistance to insulin.5
Rosiglitazone, a member of the thiazolidinedione drug class, is an antidiabetic
agent that is a modulator of the peroxisome proliferator-activated receptor (PPAR). 
The drug improves insulin resistance in patients with type 2 DM by increasing
insulin sensitivity in the liver, adipose tissue, and muscle.6,7 This, in turn, leads to 
improvement in insulin-mediated glucose disposal and hence to a decrease in insulin
requirement.8 Since thiazolidinediones can be used effectively in reducing blood
glucose concentration and insulin resistance in diabetic patients with chronic kidney
diseases, it is worth determining whether the same effects will be found in nondia-
betic patients with renal impairment. However, there is a growing recognition that 
edema can occur in patients treated with either rosiglitazone or pioglitazone.9–11
People with type 2 DM are at increased risk for cardiovascular diseases; therefore, the 
edema that sometimes accompanies the use of a thiazolidinedione is a concern because 
it might indicate congestive heart failure.12,13 Hong et al14 found that PPAR-γ activa-
tion may enhance sodium reabsorption in the cortical collecting ducts via regulation 
of the epithelial sodium channel (ENaC), resulting in peripheral edema. Human 
379
P. Aramwit et al.
ENaC is expressed in the distal portion of the renal tubule and is regulated by aldos-
terone and vasopressin. The channel plays an important role in the regulation of 
sodium balance, blood volume, and blood pressure by sodium reabsorption.15 In pa-
tients with renal deficiency, ENaCs do not function properly, resulting in reduced
sodium reabsorption. Because of this, we hypothesized that the peripheral edema
caused by thiazolidinedione administration should not occur in patients with end-
stage renal disease.
In addition to its effect on edema that may relate to weight gain, rosiglitazone also
has a demonstrable effect on metabolic factors. It has been reported that thiazolidine-
diones redistribute adipose tissue from visceral fat mass to peripheral (subcutaneous)
tissue, resulting in weight gain.16–18 Apart from those mechanisms, weight gain after
thiazolidinedione administration may result from increased eating, since blood glucose
concentration can be well controlled with thiazolidinediones and patients may experi-
ence increased appetite.19
This study was designed to investigate the effectiveness and tolerability of rosiglita-
zone on insulin resistance and body composition in nondiabetic patients undergoing
CAPD. The effectiveness of rosiglitazone in reducing insulin resistance was assessed
using the Homeostasis Model Assessment Index of Insulin Resistance (HOMA-IR). 
We studied the tolerability of rosiglitazone in CAPD by monitoring changes in body 
composition assessed by bioelectrical impedance analysis (BIA) and changes in lipid 
profiles and other laboratory data in conjunction with peripheral edema.
PATIENTS AND METHODS
Patients
Patients aged ≥18 years undergoing CAPD without DM (either type 1 or 2) who
came for a physician appointment at Phramongkutklao Hospital (Bangkok, Thailand)
between February and July 2008 were recruited into the study. Patients were eligible
for the study if, for ≥90 days before enrollment, both their fasting blood glucose 
[FBG] concentration was <5.5 mmol/L and they had not taken a thiazolidinedione. 
They had to have been undergoing CAPD, have normal liver function, and be free of 
peritonitis for ≥3 months before entering the study. Additional inclusion criteria were
an absence of residual renal function and no peritoneal failure.
Patients were excluded from the study if they had any acute illness, abnormal liver 
function tests, chronic liver disease, chronic infection (eg, tuberculosis or HIV), malig-
nancy, autoimmune disease, lupus nephritis, cardiovascular disease (eg, ischemic heart
disease or congestive heart failure), or recent gastrointestinal hemorrhage. In addition,
patients who had received any medications that could potentially result in insulin resis-
tance (eg, β-blockers, corticosteroids, verapamil, diltiazem, phenytoin, thyroid hormone,
risperdal, haloperidol, and fibrate) within the past 3 months were excluded.
CAPD patients without DM who had a single pool Kt/V >1.2 (where K is the dia-
lyzer clearance of urea, t is the dialysis time, and V is the patient’s total body water) were 
enrolled. All patients routinely had 2-L 1.5% dialysate changes 4 times a day.
Written informed consent was obtained from all study participants after a thor-
ough discussion of the protocol, its rationale, and potential risks. The protocol was 
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approved by the Ethics Committee of the Institutional Review Board of Phramong-
kutklao Hospital.
Methods
The study was conducted at Phramongkutklao Hospital. Eligible patients were
enrolled in a 12-week pretest and posttest study with a repeated-measure design. The
patients were required to visit the hospital at 4, 8, and 12 weeks after enrollment. 
Throughout the study, patients were instructed to follow a weight-maintenance diet 
and they consulted with a dietician at each visit. The patients were instructed to con-
tinue their regular medications (antihypertensive drugs, erythropoietin, and lipid-
lowering drugs) throughout the study. 
Patients were administered rosiglitazone maleate 2 mg* BID for 12 weeks. Ad-
herence was monitored by pill count at each visit. All measurements (eg, insulin 
resistance, body composition, edema, lipid profiles) were performed at 0 (baseline), 
4, 8, and 12 weeks.
Assessment of Insulin Resistance
Insulin resistance was assessed using the HOMA-IR, originally described by Mat-
thews et al,20 in which HOMA-IR (mmol/L × μIU/mL) = fasting glucose (mmol/L) ×
fasting insulin (μIU/mL)/22.5. The HOMA-IR score correlates closely with the insu-
lin sensitivity index measured using the gold standard—the euglycemic hyperinsu-
linemic clamp.21,22 The index can be applied to patients with renal failure.23
Bioelectrical Impedance Analysis Measurement of Body Composition
Changes in body composition (water and fat composition) associated with rosiglita-
zone therapy were assessed using BIA (Bioscan 916, Maltron International Ltd., Essex,
United Kingdom). Weight was measured after the dialysate solution was completely
removed from the patient.
Blood Sampling and Assays
Before starting a dialysis session, blood was drawn in the morning after an over-
night fast of ≥12 hours. Whole blood, which was used to measure hematocrit and
hemoglobin concentration, was analyzed within 2 hours after it was drawn. EDTA-
plasma was used to measure glucose, insulin, and lipid concentrations. Samples in 
EDTA-containing tubes were centrifuged immediately and the plasma was stored at
–20°C until assayed. Serum was used for other biochemical assays (eg, hepatic enzyme 
activities). Freshly drawn blood was centrifuged immediately and the serum was 
stored at –20°C until analyzed.
Physical Examination
Peripheral edema was assessed by physical examination by the 3 study investiga-
tors (O.S., P.B., and P.A.). The degree of edema was scored visually as: +1 (very mild, 
*Trademark: Avandia® (GlaxoSmithKline, Research Triangle Park, North Carolina).
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<10%); +2 (mild, ≥10% to <25%); +3 (moderate, ≥25% to <50%); and +4 (severe,
≥50%).24 For very mild edema (<10%), skin showed deeper furrowing than normal; 
and increasing edema grades resulted in a decrease of furrows. At severe edema stage 
(≥50%), no skin furrow was found. To minimize the bias from personal evaluation, 
body composition using BIA was measured at the time the physical examination
was conducted.
Statistical Analysis
The objectives of the study were to assess the effect of rosiglitazone on insulin re-
sistance and body composition. Based on the findings of a previous study,25 the dif-
ference in the mean HOMA-IR score in the patients at baseline and after 12 weeks of 
treatment was 1.1, with 5% significance and 80% power; therefore, a sample size of 
12 patients was considered sufficient. Statistical analysis was performed using SPSS 
version 10.0 (SPSS Inc., Chicago, Illinois). Results were expressed as mean (SD). Sub-
set post hoc analyses were performed for FBG and fasting plasma insulin concentra-
tions and HOMA-IR score to compare the differences between baseline and weeks 4, 
8, and 12 of treatment. Corrections for multiple comparisons were not done. The 
statistical significance of the subset post hoc analysis was assessed using the Friedman
test. A within-patient comparison of multiple analyses of water content in patients
(eg, total body water, extracellular fluid, plasma fluid, interstitial fluid) between base-
line and posttreatment (week 12) was analyzed using the Wilcoxon signed rank test. 
All statistical tests for differences were 2-tailed with α = 0.05. P < 0.05 was consid-
ered statistically significant.
RESULTS
Patients
Of the 38 patients with CAPD treated between February and July 2008, a total of 
25 potential participants were excluded because they did not meet the inclusion cri-
teria. Thirteen patients (mean [SD] age, 54.17 [11.42] years [range, 35–85 years]; 
body mass index (BMI), >20 to <30 kg/m2; FBG concentration, <5.39 mmol/L) were
included in the study. One patient was withdrawn at week 12 due to illness unrelated 
to the study. 
Insulin Resistance by HOMA-IR
The patients receiving CAPD therapy had no significant difference in FBG con-
centration between baseline and posttreatment (5.45 [0.59] vs 5.24 [0.51] mmol/L),
but they did have significantly lower fasting plasma insulin concentrations 
(28.50 [23.70] vs 10.15 [4.22] μIU/mL; P = 0.01) and HOMA-IR scores (6.70 
[5.23] vs 2.40 [1.15]; P = 0.006) (Figure 1). None of the patients experienced 
hypoglycemia.
Laboratory Profiles
There were no significant differences in any of the lipid concentrations be-
tween baseline and posttreatment (total cholesterol [TC], 176.00 [64.27] vs
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186.09 [56.02] mg/dL; LDL-C, 97.08 [27.25] vs 104.91 [32.17] mg/dL; triglyceride
[TG], 215.36 [259.30] vs 198.33 [242.29] mg/dL; and HDL-C, 48.92 [17.87] vs
45.36 [19.11] mg/dL, respectively) (Table). The mean FBG concentration at baseline
was 5.45 (0.59) mmol/L (range, 4.27–6.00 mmol/L).
No significant differences were found in blood pressure or liver enzyme activities in 
these patients at baseline compared with week 12. There were also no significant changes 
in mean (SD) weight (61.12 [6.30] vs 62.57 [6.06] kg) or BMI (22.97 [1.72] vs 23.23
[1.53] kg/m2) between baseline and posttreatment, respectively. However, 7 of the 12 pa-
tients (58.3%) showed an increase in weight after taking rosiglitazone for 4 weeks. 
Patients’ weight slowly decreased after taking rosiglitazone for 8 and 12 weeks.
Mean weight increase compared with baseline was 16.57 [37.47] kg after week 4, 3.82 
[1.57] kg after week 8, and 4.30 [2.68] kg after week 12.
Body Composition
After week 4 of treatment, 5 patients (41.7%) were found to have peripheral edema—
3 had moderate edema and 2 had mild edema. The edema decreased over time; after 
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Figure 1. Fasting blood glucose (FBG) concentration, fasting plasma insulin (FPI) concen-
tration, and Homeostasis Model Assessment Index of Insulin Resistance 
(HOMA-IR) scores at baseline and after receiving rosiglitazone for 4, 8, and 
12 weeks. HOMA-IR (mmol/L × μIU/mL) = fasting glucose (mmol/L) × fasting 
insulin (μIU/mL)/22.5. Analyzed using the Friedman test. *P = 0.005 versus 
baseline; †P = 0.011 versus baseline; ‡P = 0.01 versus baseline; §P = 0.006
versus baseline.
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Table. Laboratory profile of Thai patients without diabetes mellitus undergoing continu-
ous ambulatory peritoneal dialysis at baseline and after 12 weeks of rosiglitazone
treatment (N = 12).
Parameter Baseline Week 12 Δ P*
Weight, kg
Mean (SD) 61.12 (6.30) 62.57 (6.06) 1.13 (1.97) 0.176
Range 49.14–80.23 48.23–78.45
BMI, kg/m2
Mean (SD) 22.97 (1.72) 23.23 (1.53) 0.43 (0.85) 0.128
Range 19.24–26.55 18.89–26.73
SBP, mm Hg
Mean (SD) 141.42 (19.58) 128.91 (30.26) –14.18 (27.48) 0.099
Range 120–180 90–201
DBP, mm Hg
Mean (SD) 84.67 (13.92) 82.18 (14.52) –2.27 (13.85) 0.541
Range 60–113 70–108
TC, mg/dL
Mean (SD) 176.00 (64.27) 186.09 (56.02) 10.18 (36.25) 0.423
Range 100–349 87–318
TG, mg/dL
Mean (SD) 215.36 (259.30) 198.33 (242.29) –22.18 (78.34) 0.534
Range 57–934 44–916
HDL-C, mg/dL
Mean (SD) 48.92 (17.87) 45.36 (19.11) –1.82 (17.98) 0.959
Range 34–82 24–86
LDL-C, mg/dL
Mean (SD) 97.08 (27.25) 104.91 (32.17) 7.27 (29.41) 0.386
Range 53–130 54–138
AST, IU/L
Mean (SD) 29.42 (24.05) 28.80 (16.86) –3.00 (22.85) 0.917
Range 14–96 14–61
ALT, IU/L
Mean (SD) 23.42 (18.25) 24.50 (12.25) 0.80 (14.73) 0.779
Range 4–65 11–56
BMI = body mass index; SBP = systolic blood pressure; DBP = diastolic blood pressure; TC = total
cholesterol; TG = triglyceride; AST = aspartate aminotransferase; ALT = alanine aminotransferase.
*Wilcoxon signed rank test.
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week 8, a total of 4 patients (33.3%) were found to have edema—2 had moderate 
edema and 2 had mild edema. After 12 weeks of rosiglitazone administration, 2 pa-
tients (16.7%) had mild edema.
Figure 2 shows the mean (SD) body composition of the patients at baseline and
after 4, 8, and 12 weeks of rosiglitazone treatment. The Friedman test indicated a
significant increase between baseline and posttreatment in total body water (38.03
[4.55] vs 42.44 [5.99] L; P = 0.018), extracellular fluid (20.24 [3.75] vs 26.22 [8.69] L; 
P = 0.005), plasma fluid (4.29 [0.80] vs 5.20 [0.93] L; P = 0.005), and interstitial 
fluid (14.99 [2.78] vs 17.68 [3.07] L; P = 0.040).
We further investigated the body composition of the 7 patients who experienced
weight gain after 4 weeks of treatment. At compared with baseline, week 4, these pa-
tients were found to have a significant increase in both total body water (39.07 [4.47] 
vs 45.58 [13.27] L; P = 0.018) and extracellular fluid (21.29 [4.39] vs 24.28 [4.96] L; 
P = 0.018). For the same time period, the statistically significant increases in plasma 
fluid (4.50 [0.93] vs 5.14 [1.05] L; P = 0.018) and interstitial fluid (15.77 [3.26] vs 
17.98 [3.67] L; P = 0.018) were related to an increase in extracellular fluid.
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Figure 2. Body composition (fat mass [FM], total body water [TBW], extracellular fluid 
[ECF], plasma fluid [PF], and interstitial fluid [IF]) at baseline and after 4, 8, 
and 12 weeks of rosiglitazone treatment using bioelectrical impedance analy-
sis. Analyzed using the Friedman test. *P = 0.018 versus baseline; †P = 0.005 
versus baseline; ‡P = 0.040 versus baseline.
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Tolerability
No hypoglycemic episodes were observed. No elevation of serum transaminase 
activities was found after 12 weeks of treatment. There was no significant difference
in aspartate aminotransferase (29.42 [24.05] vs 28.80 [16.86] IU/L) or alanine amino-
transferase levels (23.42 [18.25] vs 24.50 [12.25] IU/L) between baseline and 
posttreatment.
DISCUSSION
In this study, nondiabetic uremic patients receiving CAPD therapy had a significant 
difference in HOMA-IR score (an index of insulin resistance), total body water, extra-
cellular water, plasma fluid, and interstitial fluid between baseline and posttreatment 
of rosiglitazone administration (2 mg BID). After 12 weeks of treatment, significant
reductions were also found in other components of insulin resistance syndrome (eg,
fasting plasma insulin concentration).
Insulin resistance is associated with arterial wall changes, coronary artery disease,
and cardiovascular mortality in patients with chronic kidney diseases.26,27 The use of 
rosiglitazone 4 mg/d was associated with significantly lower fasting plasma insulin 
concentrations and HOMA-IR scores after 12 weeks of treatment without hypoglyce-
mic episodes in these nondiabetic patients, similar to the results reported by Lin et 
al.25 The present pilot study found that rosiglitazone administration for 12 weeks was
associated with an apparent increase in weight, but not a statistically significant in-
crease in these patients.
No abnormal liver function tests associated with rosiglitazone administration were
found in this study. Our findings regarding lipid profiles suggest that TC and LDL-C
increased by ~5.8% and ~8.1%, respectively, compared with baseline, while TG and
HDL-C decreased by ~8.2% and ~6.9%, respectively, between baseline and 12 weeks 
of treatment. However, there were no significant differences in any of the lipid con-
centrations between baseline and posttreatment, and the results were consistent with 
those reported by other researchers. O’Moore-Sullivan and Prins28 found that patients 
treated with rosiglitazone for 16 months experienced an increase of TC and LDL-C 
concentrations by 15% to 20% during the first few months of therapy but not at a 
significant level. Yki-Järvinen29 found that rosiglitazone, after 26 weeks of treatment
at a dose of 4 to 8 mg/d, was associated with a significant decrease in TG concentra-
tion by 9% from baseline. In addition, the reduction in HDL-C concentration associ-
ated with rosiglitazone treatment has been reported in previous studies.30,31
Rosiglitazone may increase fat mass by shifting visceral fat to subcutaneous fat.32 Our
study found no significant changes in fat mass after 12 weeks of rosiglitazone therapy.
We hypothesized that the mean (SD) weight increase of 4.30 (2.68) kg after 12 weeks
of treatment in these 7 patients might have been associated with an elevation of total 
body water that resulted in peripheral edema of 6.50 (12.16) L; it was not related to fat
mass, which decreased by 1.27 (0.74) kg after week 4 of treatment. This suggests that
the change in body weight was related to nonfat components (eg, water composition).
These results are not consistent with those of Carey et al,33 which examined the
effect of rosiglitazone (8 mg/d in 2 divided doses for 16 weeks) in a randomized,
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double-blind, placebo-controlled study in patients with type 2 DM. They found a
significant increase in fat mass, whereas the increase in fat free mass was not signifi-
cant in patients with type 2 DM receiving rosiglitazone. The differences in the find-
ings of the 2 studies may be due to differences in rosiglitazone dose and treatment 
duration. Also, the previous study was evaluated in European patients with type 2 
DM who had higher body fat content than Asian CAPD patients without DM.34,35
Thiazolidinediones have been reported to directly stimulate lipogenic genes and in-
crease adipose tissue mass36,37; therefore, patients with a high percentage of fat may
show a higher degree of activation, resulting in an increase in fat mass.
Because a strong relationship between insulin resistance and chronic kidney dis-
eases among nondiabetic patients has been reported,38 detection and treatment of 
insulin resistance should be considered, even in nondiabetic patients with chronic
kidney diseases.
Limitations
A limitation of this study was its design as an observational study using a pretest
and posttest with a repeated-measure design. Although our results were statistically 
significant, this does not imply clinical significance unless a large sample size is
used and the study design controls for other confounding factors. Statistical signifi-
cance may not represent clinical importance or relevance to patient care. Elevation 
of serum transaminase activities was not found to be statistically significant. This 
may be due to the duration of the study or the small sample size, which may not 
have been sufficient to note significant differences in liver function tests or other
end points. Furthermore, bias in peripheral edema evaluation might have occurred,
since the physicians who performed the physical examinations were aware of the
study objectives. Therefore, future study should be carried out in large, double-
blind, randomized, controlled trials. The mechanism of peripheral edema after
thiazolidinedione use in patients with chronic kidney disease should also be inves-
tigated further.
This pilot study investigated only a small number of patients; changes in patient
management should not be made based on these preliminary findings alone. For sta-
tistical analysis, the α value of 0.05 was used to detect important differences. How-
ever, an α level of 0.001 would yield a more sensitive significant difference with a
higher degree of detection.
CONCLUSIONS
Administration of rosiglitazone (2 mg BID) for 12 weeks was associated with
significantly reduced fasting plasma insulin concentration as well as insulin re-
sistance in this small number of Thai patients without DM undergoing CAPD.
Total body water and extracellular water increased significantly from baseline af-
ter 12 weeks of rosiglitazone administration; however, after 12 weeks of treat-
ment, mild peripheral edema was found in 2 of these patients (15.4%). During
rosiglitazone therapy, no hypoglycemic episodes or abnormal liver function levels 
were observed.
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